Guidance
Interesting shortcuts
EFFRA Members' Perspectives
News Dashboard
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
Company perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards, technical committees and working groups
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
MiE WP26-27 Consultation - Potential Research Topics only
MiE WP26-27 Consultation and context pointers
MiE WP26-27 Consultation with pointers to WP25-27 consultation
MiE KPIs
Relevant (future) calls
EU-Programme-Call
NACE code
EFFRA Organisations - members
EFFRA WG pointers
Pathways
Pathways
Projects
Projects
Resources
Resources
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
NMBP-12-2017 Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices
Associated lists
In list:
EU-Programme-Call
EU-Programme-Call
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.3. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
H2020-EU.2.1.3.0. Cross-cutting call topics
H2020-NMBP-2017-two-stage
NMBP-12-2017 Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices